Stated Ballyhoo On The ABT-737

22%, P http://www.selleckchem.com/products/Nutlin-3.html nilotinib as options with a category 1 recommendation for initial treatment of CML-CP [25]. Second generation TKIs have shown inducing higher rates of early optimal responses; their impact on long-term over survival remains to be determined. Allo-HSCT or other chemotherapy agents are not any longer recommended as upfront treatments for CML-CP given the excellent outcomes and long-term survival achieved with the TKIs. The IRIS trial demonstrated that early response to therapy with imatinib was related to improved long-term outcomes, and it highlighted two major treatment endpoints: CCyR and MMR. In a study by Hughes et al., overall freedom from progression http://www.selleck.cn/products/Methazolastone.html (FFP) for those who had attained a CCyR at 12 months was significantly higher when compared to those who did not (95% vs. 85%; P http://www.selleckchem.com/products/ABT-737.html evolution during treatment at any time is also considered treatment failure. These patients warrant change of therapy. Suboptimal responses are those that do not meet criteria for optimal response or those for failure but represent a slow or inadequate response. A suboptimal response early in therapy is more prognostic than at later time points. Patients with a suboptimal response at 6 months have similar outcomes in terms of OS, progression free survival (PFS), and EFS as those with failure to therapy.